Sickle Cell Disease Market

Market Overview:

The 7 major Sickle Cell Disease markets reached a value of US$ 775.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,904.2 Million by 2034, exhibiting a growth rate (CAGR) of 8.5% during 2024-2034.

The Sickle Cell Disease market is expected to be driven by a strong pipeline of late-stage drugs that offer a strong efficacy and safety profile. Gene therapies represent the most promising drug candidates, although costly, they are expected to offer patients a cure that avoids a painful and risky bone marrow transplant. Furthermore, diagnosis and treatment rates for sickle cell disease have also improved significantly, creating a positive impact on the market.

Sickle Cell Disease (SCD) is a form of inherited blood disorder. Patients with Sickle cell disease have abnormal hemoglobin. This causes the red blood cells to become hard and sticky and appear like a C-shaped farm tool called a “sickle.” The sickle cells die early, resulting in a constant shortage of red blood cells. Signs and symptoms of sickle cell anemia normally appear around 6 months of age. They vary from one individual to another and may change over time. Common symptoms can include anemia, episodes of pain, swelling of hands and feet, frequent infections, delayed growth or puberty, vision problems, etc. Sickle Cell Disease is a genetic disorder that is present at birth. It is inherited when an individual receives two genes - one from both parents that code for abnormal hemoglobin.

IMARC Group’s new report "Sickle Cell Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Sickle Cell Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Sickle Cell Disease market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Sickle Cell Disease across the seven major markets. According to the report, among the seven major markets, the United States have the largest patient pool for Sickle Cell Disease and represent the largest market for Sickle Cell Disease treatment. Furthermore, the current Sickle Cell Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Sickle Cell Disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current, and Future Epidemiology Scenario
• Historical, Current, and Future Performance of the Sickle Cell Disease Market
• Historical, Current, and Future Performance of Various Therapeutic Categories in the Sickle Cell Disease Market
• Sales of Various Drugs Across the Sickle Cell Disease Market
• Reimbursement Scenario in the Sickle Cell Disease Market

Competitive Landscape:

This report also provides a detailed analysis of the current Sickle Cell Disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Sickle Cell Disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
• What was the country-wise size of the Sickle Cell Disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Sickle Cell Disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Sickle Cell Disease market?

Epidemiology Insights

• What is the size of the Sickle Cell Disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) of Sickle Cell Disease across the seven major markets?
• What are the key factors driving the epidemiological trend of Sickle Cell Disease?
• What will be the growth rate of Sickle Cell Disease patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current marketed Sickle Cell Disease drugs and what are their market performance?
• What are the key pipeline Sickle Cell Disease drugs and how are they expected to perform in the coming years?
• How safe are the currently marketed Sickle Cell Disease drugs and what are their efficacies?
• How safe are the late-stage pipeline Sickle Cell Disease drugs and what are their efficacies?
• What are the current treatment guidelines for Sickle Cell Disease drugs across the seven major markets?
• Who are the key companies in the Sickle Cell Disease market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Sickle Cell Disease market?